drugset / Trial / NCT04620161

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

NCT04620161

Phase 2 Completed 181 enrolled Anji Pharma Covance · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of pradigastat 20 and 40 mg as compared to placebo in patients with Functional Constipation.

Timeline

Start
2020-09-22
Primary completion
2022-04-30
Completion
2022-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pradigastat Small molecule 20 mg Oral
Subject Pradigastat Small molecule 40 mg Oral

Indications